Growth factors are the input that decides whether cultivated meat has a cost curve. They are also the input with the least public price information of anything in this industry — less than feedstock sugar, which has a commodity quotation, and less than bioreactor steel, which now has a vendor cost model with published footnotes.
ORF Genetics, based in Kópavogur, Iceland, produces recombinant growth factors in bioengineered barley seeds and sells them under the MESOkine brand. FoodNavigator reported in May 2026 that the company supplies “around 150 companies worldwide”, naming Mosa Meat and Vow; ORF’s own product page carries endorsements from Mosa Meat and Aleph Farms. That is a very large share of a small industry buying from one supplier.
The only price figure ORF has published, as far as we can find, dates from September 2020: prices “50% to 60% lower than competitors”, linked to a product-list page. The competitors are not named. No absolute figure — euros per gram, per milligram, per litre of medium at working concentration — appears in any ORF material or trade coverage we have read, including coverage published this year.
What is actually being sold
This matters more than it sounds, because the product is not the thing the comparison implies.
From ORF’s product page: “MESOkine is a defined barley seed extract, containing the purified recombinant growth factor along with selected barley seed proteins. The barley seed proteins serve as stabilizing proteins that can prolong the lifetime of the recombinant protein and may enhance the bioactivity of growth factors in standardized bioassays.”
And on how equivalence is established: “Each batch of MESOkine is confirmed to have comparable bioactivity to a corresponding commercial source of highly purified (>95%) growth factor.”
So the unit being sold is a seed extract whose active content is not the whole mass, benchmarked on bioactivity against a >95%-pure reference product. ORF’s CSO Björn Örvar has described the underlying insight plainly: the company’s “discovery that animal growth factors for cultivated meat do not need to be highly purified has further shifted the cost equation”, because simplifying downstream processing is where the cost comes out.
That is a legitimate and probably correct engineering argument. It also means:
| Conventional E. coli growth factor | MESOkine | |
|---|---|---|
| Form | purified recombinant protein, >95% | defined barley seed extract with stabilising seed proteins |
| Basis for comparison | mass of protein | bioactivity in standardised bioassay vs a >95% reference |
| Downstream processing | full purification train | simplified |
| Published absolute price | none found | none found |
| Published relative price | not applicable (it is the reference) | “50% to 60% lower than competitors” (2020) |
Practical consequence. A price per gram is meaningless across these two products, because a gram of extract and a gram of purified protein are not the same quantity of activity. If you are comparing suppliers, the only defensible unit is cost per unit of bioactivity at your own working concentration, measured in your own cells. Anyone quoting a per-gram saving across the two formats is repeating the basis error that runs through every cost claim in this sector.
A 50–60% discount against a benchmark nobody names
The 2020 discount claim has now been repeated in 2026 coverage. It has three problems, none of them fatal and all of them worth stating.
It is six years old, published before MESOkine had been through the bovine, porcine and avian testing programme the same article says was due to start in late 2021. It is relative to unnamed competitors, in a market where the reference product is a research-grade reagent whose list price bears little relationship to what a scaled buyer pays. And it sits alongside a free-sample distribution strategy — Örvar has described giving samples to cultivated meat startups so they could run direct comparisons — which is a rational go-to-market move and also a mechanism that delays price discovery. A market where the leading supplier’s product often arrives free does not generate observable prices.
The comparison ORF makes on quality is more useful than the one it makes on price: batch bioactivity verified against a commercial >95% reference by independent research organisations. That is a testable, repeatable claim, and it is the one a buyer should ask to see the data behind.
The capacity claim has no base
ORF raised €5 million (US$5.5 million) in September 2025 and said it planned to increase the round to €7 million by mid-October. On the strength of it, the company said the investment “will allow it to scale capacity fourteenfold by 2027 and by a factor of 10,000 by 2032.”
Fourteen times what? Ten thousand times what? No base volume is published — not kilograms of extract, not grams of active growth factor, not hectares or greenhouse area at any date more recent than 2020, when Green Queen described a 2,000 square metre greenhouse on the Reykjanes Peninsula holding up to 130,000 barley plants at a time.
This is exactly the pattern we found when a 4x capacity multiple turned out to have no published base. A multiplier without a base is not a capacity figure; it is a direction. For a buyer trying to establish whether one supplier can underwrite an industry’s scale-up, the direction is not enough.
Practical consequence. Before signing a supply agreement, ask for the current annual output in grams of active growth factor and the 2027 committed figure in the same unit. If the supplier will not put a base under the multiplier, the multiplier should not enter your model.
The concentration is real, and partly by design
Three structural facts sit behind the 150-customer figure.
One crop, one production system. Growth factors are expressed in barley seed via ORF’s Orfeus system, selected over E. coli and yeast. The seeds are the inventory: FoodNavigator quotes Örvar noting that proteins in stored barley seed “remain intact for extended periods”, and that seeds are easy to stockpile. That is a genuine supply-chain strength — a buffer stock of active material that needs no cold chain — and it is unusual in an input layer otherwise built on frozen vials.
Geographic spread is being built, from a narrow base. Most barley is grown in ORF’s Icelandic greenhouses on geothermal energy; the company also grows in Canada and is piloting production in Chile and Argentina. CEO Berglind Rán Ólafsdóttir has made the cost argument for open-field growing over greenhouses, and for food-grade rather than pharma-grade processing.
The product is a GM crop. Örvar has been explicit about the friction: “In the early 2000s, we avoided developing plants with agricultural traits due to the strong anti-GMO sentiment… Despite overwhelming scientific consensus on GMO safety, public and political resistance remains.” A cultivated meat product made in Europe using a growth factor expressed in genetically modified barley inherits that argument even though no modified material is in the food.
Where the supply chain disappears from the record
Here is the part that should concern anyone thinking about traceability rather than cost.
Singapore’s newly published List of Approved Novel Foods is the most detailed public regulatory record of cultivated meat production that exists. Its media descriptions are compositional, not commercial: the 2020 cultured chicken entry names “basal media (DMEM/F12)… supplemented with FBS”; the October 2025 cultivated chicken biomass entry lists “sugars, vitamins, amino acids, proteins, minerals, polyamines, vegetable fat and anti-shearing agent”. Nowhere does a supplier name appear, and nor should it — a specification is not a purchase order.
The consequence is that the most cost-critical and most concentrated input in cultivated meat is invisible in every public record: no price, no supplier identity in the regulatory file, and volumes described only as multiples. When we traced a claim that transferrin was 95% of media cost back to its source, the error had survived because nobody could check the underlying numbers. The same conditions still hold.
Practical consequence. For a food business doing supplier due diligence on a cultivated product, the media supply chain has to be established by direct enquiry — it cannot be assembled from public documents. Ask which growth factors, from which supplier, at what purity basis, with what second source. The one disclosure of this kind we have seen from a producer, Meatly’s bioreactor and medium cost figures, is notable precisely because it is nearly alone.
The counter-argument
None of this is unusual for a business-to-business ingredient. Specialty ingredient prices are contract-specific, volume-dependent and routinely confidential; enzyme suppliers, culture houses and flavour companies publish no list prices either. Free samples are standard practice for a new format that a customer must qualify in their own process. And ORF has disclosed things its competitors have not: the product’s actual composition, the bioactivity benchmark, and third-party verification of it.
There is a stronger version of the objection. A single supplier serving most of an industry is only a risk if the industry is scaling; today it is contracting, with the supply layer shutting down faster than the producers. A concentrated supplier that stays solvent through the trough may be more valuable to its customers than a fragmented market that does not.
Both points are fair. Neither changes the practical position of a buyer who cannot compare two quotations on a common basis.
What we could not establish
- Any absolute price for MESOkine, current or historical, in any currency or unit.
- Whether the “50% to 60% lower” claim is still current. It dates from September 2020 and pointed at a product-list page; we could not retrieve a current price list.
- The base behind “fourteenfold by 2027” and “10,000-fold by 2032”. No unit or starting volume is published.
- Whether the €5m round reached its €7m target. It was described as open in September 2025; we found no later confirmation.
- How many of the roughly 150 customers are paying accounts rather than recipients of R&D samples. The figure is reported without that distinction.
- Current greenhouse capacity. The 2,000 m² and 130,000-plant figures are from 2020 and may well be superseded.
What to watch
- Any absolute price entering the record. A single published figure — even one number, in one currency, at one purity basis — would let every cultivated meat cost model in circulation be checked for the first time.
- Whether a second supplier reaches scale. Molecular-farming competitors exist; if one publishes volumes or prices, the concentration question resolves itself commercially rather than editorially.
- The 2027 fourteenfold milestone. It is close enough to be testable, and it will be testable only if a base is published before then.
- Whether growth factor sourcing shows up in a regulatory dossier. If any jurisdiction begins recording input suppliers rather than input specifications, the traceability gap described here closes on its own.